Literature DB >> 27390349

Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.

Daniela Gasparotto1, Sabrina Rossi2, Maurizio Polano1, Elena Tamborini3, Erica Lorenzetto1, Marta Sbaraglia2, Alessia Mondello1, Marco Massani4, Stefano Lamon5, Raffaella Bracci6, Alessandra Mandolesi6, Elisabetta Frate7, Franco Stanzial8, Jerin Agaj9, Guido Mazzoleni10, Silvana Pilotti3, Alessandro Gronchi11, Angelo Paolo Dei Tos2, Roberta Maestro12.   

Abstract

PURPOSE: The majority of gastrointestinal stromal tumors (GIST) are driven by KIT, PDGFRA, or, less commonly, BRAF mutations, and SDH gene inactivation is involved in a limited fraction of gastric lesions. However, about 10% of GISTs are devoid of any of such alterations and are poorly responsive to standard treatments. This study aims to shed light on the molecular drivers of quadruple-negative GISTs. EXPERIMENTAL
DESIGN: Twenty-two sporadic quadruple-negative GISTs with no prior association with Neurofibromatosis Type 1 syndrome were molecularly profiled for a panel of genes belonging to tyrosine kinase pathways or previously implicated in GISTs. For comparison purposes, 24 GISTs carrying KIT, PDGFRA, or SDH gene mutations were also analyzed. Molecular findings were correlated to clinicopathologic features.
RESULTS: Most quadruple-negative GISTs featured intestinal localization, with a female predilection. About 60% (13/22) of quadruple-negative tumors carried NF1 pathogenic mutations, often associated with biallelic inactivation. The analysis of normal tissues, available in 11 cases, indicated the constitutional nature of the NF1 mutation in 7 of 11 cases, unveiling an unrecognized Neurofibromatosis Type 1 syndromic condition. Multifocality and a multinodular pattern of growth were common findings in NF1-mutated quadruple-negative GISTs.
CONCLUSIONS: NF1 gene mutations are frequent in quadruple-negative GISTs and are often constitutional, indicating that a significant fraction of patients with apparently sporadic quadruple-negative GISTs are affected by unrecognized Neurofibromatosis Type 1 syndrome. Hence, a diagnosis of quadruple-negative GIST, especially if multifocal or with a multinodular growth pattern and a nongastric location, should alert the clinician to a possible Neurofibromatosis Type 1 syndromic condition. Clin Cancer Res; 23(1); 273-82. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27390349     DOI: 10.1158/1078-0432.CCR-16-0152

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  What is New in Gastrointestinal Stromal Tumor?

Authors:  Inga-Marie Schaefer; Adrián Mariño-Enríquez; Jonathan A Fletcher
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

2.  Gastrointestinal stromal tumors-are we stuck and the way forward.

Authors:  Umang Swami; Varun Monga; Mohammed Milhem
Journal:  Transl Gastroenterol Hepatol       Date:  2017-11-20

3.  The Call of "The Wild"-Type GIST: It's Time for Domestication.

Authors:  Maha Alkhuziem; Adam M Burgoyne; Paul T Fanta; Chih-Min Tang; Jason K Sicklick
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

4.  Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis.

Authors:  Katherine E Fero; Taylor M Coe; Paul T Fanta; Chih-Min Tang; James D Murphy; Jason K Sicklick
Journal:  JAMA Surg       Date:  2017-05-01       Impact factor: 14.766

Review 5.  New treatment strategies for advanced-stage gastrointestinal stromal tumours.

Authors:  Lillian R Klug; Homma M Khosroyani; Jason D Kent; Michael C Heinrich
Journal:  Nat Rev Clin Oncol       Date:  2022-02-25       Impact factor: 66.675

Review 6.  [Mesenchymal tumors and tumor-like lesions of the gastrointestinal tract: an overview].

Authors:  Abbas Agaimy
Journal:  Pathologe       Date:  2021-12-17       Impact factor: 1.011

7.  FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.

Authors:  Josephine K Dermawan; Chad M Vanderbilt; Jason C Chang; Brian R Untch; Samuel Singer; Ping Chi; William D Tap; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2022-02-22       Impact factor: 4.263

8.  Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs.

Authors:  Sabrina Rossi; Daniela Gasparotto; Matilde Cacciatore; Marta Sbaraglia; Alessia Mondello; Maurizio Polano; Alessandra Mandolesi; Alessandro Gronchi; David E Reuss; Andreas von Deimling; Roberta Maestro; Angelo Paolo Dei Tos
Journal:  Mod Pathol       Date:  2017-09-01       Impact factor: 7.842

9.  Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic NF1 and Notch Pathway Mutations.

Authors:  Adam M Burgoyne; Martina De Siena; Maha Alkhuziem; Chih-Min Tang; Benjamin Medina; Paul T Fanta; Martin G Belinsky; Margaret von Mehren; John A Thorson; Lisa Madlensky; Timothy Bowler; Francesco D'Angelo; Dwayne G Stupack; Olivier Harismendy; Ronald P DeMatteo; Jason K Sicklick
Journal:  JCO Precis Oncol       Date:  2017-08-15

Review 10.  Mesenchymal tumours of the gastrointestinal tract.

Authors:  Marta Sbaraglia; Gianluca Businello; Elena Bellan; Matteo Fassan; Angelo Paolo Dei Tos
Journal:  Pathologica       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.